Equity Research
William Blair’s equity research analyst coverage of sleep apnea machine manufacturer ResMed was featured exclusively in Medtech Dive’s coverage of the company’s change in leadership.
“ResMed’s recent restructuring of its leadership team, which created heads of product, marketing, and revenue, is part of a push to pay more attention to demand generation,” the analyst wrote in the note about the leadership change.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreWilliam Blair initiated research coverage of On Holding AG (ONON $32.87), a fast-growing performance and lifestyle brand based in Switzerland selling athletic footwear, primarily in running, but with a growing presence in newer categories and apparel.
Read moreWilliam Blair initiated research coverage of Cullinan Oncology, Inc. (CGEM $17.37), a company focused on advancing modality-agnostic targeted therapies for cancer, with a broad pipeline encompassing small molecules and multifunctional therapies across a diverse range of oncologic targets.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
